GLA
NKTR icon

Great Lakes Advisors’s Nektar Therapeutics NKTR Stock Holding History

Great Lakes Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
2,946
-795
-21% -$58.2K ﹤0.01% 795
2026
Q1 		$269K Buy
+3,741
New +$213K ﹤0.01% 716
2025
Q4 		– Sell
-3,922
Closed -$223K – 835
2025
Q3 		$223K Buy
+3,922
New +$130K ﹤0.01% 758

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Lakes Advisors's NKTR Position: Q2 2026 in Review

Great Lakes Advisors reduced its Nektar Therapeutics (NKTR) stake by 21% in Q2 2026, selling an estimated $58.2K and leaving 2,946 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #795.

Great Lakes Advisors first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. The position peaked at $269K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Great Lakes Advisors held 2,946 shares of Nektar Therapeutics worth $206K as of Q2 2026.
  • Great Lakes Advisors sold 795 Nektar Therapeutics shares in Q2 2026, an estimated $58.2K.
  • Nektar Therapeutics made up ﹤0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #795 holding.
  • Great Lakes Advisors first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Great Lakes Advisors's Nektar Therapeutics position peaked at $269K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.